|
ZNF93 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.74920000040046E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.6896000004939E-07 |
| Normal-vs-Stage2 |
4.48409999997956E-06 |
| Normal-vs-Stage3 |
3.28469999977266E-07 |
| Normal-vs-Stage4 |
3.24519999983508E-07 |
| Stage1-vs-Stage2 |
9.697400E-01 |
| Stage1-vs-Stage3 |
7.725200E-01 |
| Stage1-vs-Stage4 |
5.182200E-01 |
| Stage2-vs-Stage3 |
8.299600E-01 |
| Stage2-vs-Stage4 |
6.202000E-01 |
| Stage3-vs-Stage4 |
7.084200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.38379999470706E-08 |
| Normal-vs-AfricanAmerican |
4.983500E-04 |
| Normal-vs-Asian |
8.834200E-04 |
| Caucasian-vs-AfricanAmerican |
1.061170E-01 |
| Caucasian-vs-Asian |
1.199740E-02 |
| AfricanAmerican-vs-Asian |
6.043200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.03739999996111E-06 |
| Normal-vs-Female |
8.29949999836543E-08 |
| Male-vs-Female |
9.427600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.05599999972372E-07 |
| Normal-vs-Age(41-60Yrs) |
2.20690000052315E-07 |
| Normal-vs-Age(61-80Yrs) |
5.40169999951878E-07 |
| Normal-vs-Age(81-100Yrs) |
1.893810E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.469400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.407800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.981400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.134600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.536600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.737800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.595600E-01 |
| Classical-VS-Follicular |
4.144400E-01 |
| Classical-VS-Other |
9.492400E-01 |
| Classical-VS-Normal |
8.88099999984959E-07 |
| Tall-VS-Follicular |
7.186800E-01 |
| Tall-VS-Other |
6.532600E-01 |
| Tall-VS-Normal |
3.82980000046551E-07 |
| Follicular-VS-Other |
8.455800E-01 |
| Follicular-VS-Normal |
5.34969999965718E-07 |
| Other-VS-Normal |
4.007600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.28179999953271E-07 |
| Normal-vs-N1 |
8.6512999986077E-08 |
| N0-vs-N1 |
3.377800E-01 |
|
|
